MedPharm, the leading topical and transdermal formulation development specialist today announce the appointment of Sarah Pratt as Chief Operations Officer who will help support the company’s expansion plans.

MedPharm is delighted to announce the expansion of its senior management team with the addition of Sarah Pratt, a highly experienced pharmaceutical professional who has been appointed as Chief Operations Officer. Sarah, a registered Pharmacist, has almost 20 years’ experience within the pharmaceutical industry. She has built expertise spanning all areas of product development from formulation, manufacturing and clinical trials to registration and commercialisation. This experience has been gained across a broad range of product types and dosage forms including novel drug delivery systems and medical devices. Sarah has held senior positions with ICI (now Astra-Zeneca) and with Sanofi in the UK and France. She has also worked for organisations involved in the formulation and manufacture of unlicensed medicines and has led international, cross-industry groups as Chair of the European Investigational Medicinal Products Group.

Dr Andrew Muddle, CEO commented “Sarah’s wealth of experience and industry knowledge has already made her a key addition to the company. She will help us continue to drive growth at MedPharm as we open our first US based lab and pursue development of our proprietary drug delivery technologies.”

About the company:
MedPharm is the leading topical and transdermal pharmaceutical development company. It is recognised internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) formulations and drug delivery systems. Established in 1999, MedPharm has built a worldwide reputation for its unique and highly specialised service in contract research, development and manufacturing. The company offers a complete suite of development options from simple feasibility tests, formulation and dosage form design, optimisation and testing through to preparation of GMP clinical supplies for Phase I/II. The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical and transdermal drug delivery systems including MedSpray®, MedRo® and AquaRMed™. It has produced these innovations by exploiting its internal product development expertise and licences these technologies to MedPharm’s clients. MedPharm has both development and GMP accredited manufacturing labs in the UK and dedicated testing labs in the USA.
Delivering successful

Delivering successful topical and transdermal products for our client partners
Providing the highest level of scientific expertise to lead and guide client projects to successful conclusions
Striving for constant scientific advancement; driving scientific progression and developing unique scientific solutions
Undertaking serious scientific challenges and committing ourselves entirely to achieve product success
Passionate for our science and ensuring project success

Follow us on Linked In
Contact the business development team:

Back to News